MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) was the target of a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 17,033 shares, a decrease of 24.2% from the February 12th total of 22,470 shares. Based on an average trading volume of 112,233 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the company are short sold. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 112,233 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analyst Weigh In

A number of equities analysts have commented on MDXH shares. BTIG Research reaffirmed a “buy” rating and set a $7.00 price objective on shares of MDxHealth in a research report on Tuesday, December 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $7.75.

MDxHealth Trading Down 1.5%

Shares of NASDAQ:MDXH traded down $0.05 during trading on Friday, reaching $3.20. 48,075 shares of the stock were exchanged, compared to its average volume of 109,411. MDxHealth has a 12 month low of $1.36 and a 12 month high of $5.33. The stock has a 50-day moving average price of $3.52 and a 200-day moving average price of $3.78. The firm has a market cap of $158.40 million, a PE ratio of -4.78 and a beta of 1.61.

MDxHealth (NASDAQ:MDXH) last announced its earnings results on Thursday, February 26th. The company reported $999.00 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $999.13. The company had revenue of $29.55 million for the quarter, compared to analyst estimates of $26.05 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 31.07%. On average, sell-side analysts expect that MDxHealth will post -1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MDXH. Intesa Sanpaolo Wealth Management acquired a new stake in shares of MDxHealth during the fourth quarter worth $36,000. GSA Capital Partners LLP acquired a new position in shares of MDxHealth in the third quarter valued at about $48,000. Lido Advisors LLC acquired a new position in shares of MDxHealth in the third quarter valued at about $48,000. Jefferies Financial Group Inc. bought a new position in MDxHealth during the third quarter worth about $53,000. Finally, Squarepoint Ops LLC bought a new position in MDxHealth during the fourth quarter worth about $51,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.